Abstract:Background Systemic sclerosis (SSc) is an autoimmune disease characterized with multiple organ fibrosis. Previous studies showed transcription factor early growth response 1 (Egr1) overexpressed in the lesional skin of SSc patients, as well as Egr1 inducible genes1. Egr1 forms a positive feedback loop with master pro-fibrotic cytokine TGF and thus promotes fibrosis. Objectives To investigate the anti-fibrotic effect of a novel DMARD iguratimod in scleroderma models and patient skin grafts. Methods We used iguratimod to treat TGF-stimulated human skin fibroblast, bleomycin induced mice, tight skin 1 (TSK-1) mice and SSc skin grafts. The bleomycin model contained pre-establish fibrosis and late onset treatment. The skin grafts came from three SSc patients and was planted into irradiated nude mice. Results Iguratimod down-regulated egr1 expression in human skin fibroblast, with decreased collagen production and a-SMA expression. Knocking down Egr1 in fibroblast could mimic these effects. Both oral and topical iguratimod could reduce dermal thickening and collagen deposition in bleomycin induced skin fibrosis. a-SMA (+) myofibroblast counts, as well as Egr1 (+) and/or TGF (+) fibroblast counts in iguratimod treated groups were significantly less than the controls. Similarly, topical iguratimod ameliorated fibrosis with deduced dermal thickening in TSK-1 mice. Of note, 5-week iguratimod local injection remarkably reduced collagen content in skin grafts from three SSc patients. Staining of Egr1 and TGF in skin tissue were inhibited after iguratimod treatment simultaneously. Conclusion We found the potential of iguratimod to treat SSc, which was characterized as an Egr1 inhibitor. Further clinical investigation is needed to establish its safety and efficacy. References [1] Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS one 2011;6(9):e23082 doi: 10.1371/journal.pone.0023082 [2] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. The Journal of biological chemistry 2006;281(30):21183-97 doi: 10.1074/jbc.M603270200 [2] Wu M, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. The American journal of pathology 2009;175(3):1041-55 doi: 10.2353/ajpath.2009. Acknowledgement This work is supported by National Natural Science Foundation of China (81601401). Disclosure of Interests None declared

Ubiquitination In Scleroderma Fibrosis And Its Treatment

E3 Ubiquitin Ligase: A Potential Regulator in Fibrosis and Systemic Sclerosis

[Transforming Growth Factor-Beta and Its Receptors in Scleroderma].

The Epigenetic Regulation of Scleroderma and Its Clinical Application

Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches

Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis

Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities

Inhibition of the Hedgehog Pathway Leads to Antifibrotic Effects in Dermal Fibrosis

Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential

Immune Cell Dysregulation As a Mediator of Fibrosis in Systemic Sclerosis

Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

Role of endothelin-1 in the skin fibrosis of systemic sclerosis

Ribosomal S6 protein kinase 2 aggravates process of systemic scleroderma.

Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention

The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling.

Cellular Transdifferentiation: A Crucial Mechanism of Fibrosis in Systemic Sclerosis

THU0355 IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP

Pathogenesis of systemic sclerosis-current concept and emerging treatments

Sirtuins and Accelerated Aging in Scleroderma

Pathophysiology of systemic sclerosis (scleroderma)

Role of TGFβ-producing regulatory T cells in scleroderma and end-stage organ failure